The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Tolga Tanguler Biography and Net Worth

EVP of Alnylam Pharmaceuticals

Tolga Tanguler joined Alnylam in January 2021 and has over 20 years of global biopharmaceutical experience in a variety of marketing and commercial roles. He has worked across multiple geographies including the U.S., Europe, and emerging markets and in a broad range of small and large disease therapy areas.

Prior to joining Alnylam, Tolga served for two years as Senior Vice President and Head of Alexion U.S., where he led an organization of 700 colleagues across sales, market access, marketing, operations, and patient services. Before Alexion, he spent the majority of his career at Pfizer serving in roles of increasing responsibility, most recently as Regional President, North America for Rare Diseases and prior to that as Global Vice President and Alliance Co-Head, Eliquis, as well as and serving as a country manager of Denmark and Iceland during his tenure.

Tolga received his Bachelor of Science in Finance and Economics from Istanbul University in Turkey and his MBA in Marketing and Supply Chain Management from Michigan State University, as well as a post graduate certificate in Marketing from the University of California, Santa Barbara.

What is Tolga Tanguler's net worth?: The estimated net worth of Tolga Tanguler is at least $441,046.89 as of April 27th, 2023. Mr. Tanguler owns 1,801 shares of Alnylam Pharmaceuticals stock worth more than $441,047 as of November 23rd. This net worth approximation does not reflect any other assets that Mr. Tanguler may own. Additionally, Mr. Tanguler receives an annual salary of $971,300.00 as EVP at Alnylam Pharmaceuticals. Learn More about Tolga Tanguler's net worth.
How old is Tolga Tanguler?: Mr. Tanguler is currently 51 years old. There are 6 older executives and no younger executives at Alnylam Pharmaceuticals. The oldest executive at Alnylam Pharmaceuticals is Dr. Yvonne L. Greenstreet M.B.A., MBChB, CEO & Director, who is 61 years old. Learn More on Tolga Tanguler's age.
What is Tolga Tanguler's salary?: As the EVP of Alnylam Pharmaceuticals, Inc., Mr. Tanguler earns $971,300.00 per year. There are 4 executives that earn more than Mr. Tanguler. The highest earning executive at Alnylam Pharmaceuticals is Dr. Yvonne L. Greenstreet M.B.A., MBChB, CEO & Director, who commands a salary of $2,150,000.00 per year. Learn More on Tolga Tanguler's salary.
How do I contact Tolga Tanguler?: The corporate mailing address for Mr. Tanguler and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on Tolga Tanguler's contact information.
Has Tolga Tanguler been buying or selling shares of Alnylam Pharmaceuticals?: Tolga Tanguler has not been actively trading shares of Alnylam Pharmaceuticals during the past quarter. Most recently, Tolga Tanguler sold 1,476 shares of the business's stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $194.59, for a transaction totalling $287,214.84. Following the completion of the sale, the executive vice president now directly owns 1,801 shares of the company's stock, valued at $350,456.59. Learn More on Tolga Tanguler's trading history.
Who are Alnylam Pharmaceuticals' active insiders?: Alnylam Pharmaceuticals' insider roster includes Dennis Ausiello (Director), Michael Bonney (Director), Jeffrey Dunn (CEO), Kevin Fitzgerald (EVP), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Amy Schulman (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 154,848 shares worth more than $34,733,444.48. The most recent insider tranaction occured on August, 20th when CEO Yvonne Greenstreet sold 15,000 shares worth more than $4,200,000.00. Insiders at Alnylam Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.
Information on this page was last updated on 8/20/2024.

Tolga Tanguler Insider Trading History at Alnylam Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/27/2023	Sell	1,476	$194.59	$287,214.84	1,801
8/5/2022	Sell	1,841	$218.16	$401,632.56
8/3/2022	Sell	1,754	$210.00	$368,340.00	3,629
7/5/2022	Sell	1,754	$150.00	$263,100.00	1,754

Tolga Tanguler Buying and Selling Activity at Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $244.89

$243.35

$248.90

50 Day Range

MA: $273.54

$232.27

$300.55

2 Week Range

Now: $244.89

$141.98

$304.39

Volume

525,884 shs

Average Volume

876,685 shs

Market Capitalization

$31.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Financial Prophecy

From Porter & Company | Ad

Including the name of the #1 company to buy.

Tolga Tanguler Biography and Net Worth

What is Tolga Tanguler's net worth?

How old is Tolga Tanguler?

What is Tolga Tanguler's salary?

How do I contact Tolga Tanguler?

Has Tolga Tanguler been buying or selling shares of Alnylam Pharmaceuticals?

Who are Alnylam Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Alnylam Pharmaceuticals?